CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED

Active Cambridge

Other research and experimental development on natural sciences and engineering

0 employees website.com
Other research and experimental development on natural sciences and engineering
C

CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED

Other research and experimental development on natural sciences and engineering

Founded 5 Aug 1996 Active Cambridge, United Kingdom 0 employees website.com
Other research and experimental development on natural sciences and engineering

Previous Company Names

CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC 22 Aug 1996 — 1 Sept 2011
INTERCEDE 1186 LIMITED 5 Aug 1996 — 22 Aug 1996
Accounts Submitted 19 May 2026 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 19 Aug 2025 Next due 29 Aug 2026 2 months remaining
Net assets £3,497M £0 2024 year on year
Total assets £3,497M £0 2024 year on year
Total Liabilities £0
Charges None No charges registered

Contact & Details

Contact

Registered Address

1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom

Full company profile for CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED (03234033), an active company based in Cambridge, United Kingdom. Incorporated 5 Aug 1996. Other research and experimental development on natural sciences and engineering. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2014–2024)

Cash in Bank

N/A

Net Assets

£3497.00M

Total Liabilities

N/A

Turnover

N/A

Employees

N/A

Debt Ratio

N/A

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

4 Allotments 4 Shares £2544.85m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
25 Mar 20201£334.62m£334.62m
18 Dec 20191£405.11m£405.11m
18 Dec 20191£405.11m£405.11m
18 Dec 20171£1400.00m£1400.00m

Officers

Officers

1 active 2 resigned
Status
Iain Alistair CollinsDirectorBritishUnited Kingdom5531 May 2017Active

Shareholders

Shareholders (1)

Astrazeneca Ab
100.0%
55,279,618

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 75 To 100 Percent,right To Appoint And Remove Directors

Group Structure

Group Structure

CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED Current Company
MEDIMMUNE LIMITED united kingdom

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
19 May 2026AccountsAnnual accounts made up to 31 Dec 2025
19 Aug 2025Confirmation StatementConfirmation statement made on 15 Aug 2025 with no updates
2 Jun 2025AccountsAnnual accounts made up to 31 Dec 2024
2 May 2025OfficersAppointment of Hannah Victoria Tattersall as director on 1 May 2025
1 May 2025OfficersTermination of Adrian Charles Noel Kemp as director on 1 May 2025
19 May 2026 Accounts

Annual accounts made up to 31 Dec 2025

19 Aug 2025 Confirmation Statement

Confirmation statement made on 15 Aug 2025 with no updates

2 Jun 2025 Accounts

Annual accounts made up to 31 Dec 2024

2 May 2025 Officers

Appointment of Hannah Victoria Tattersall as director on 1 May 2025

1 May 2025 Officers

Termination of Adrian Charles Noel Kemp as director on 1 May 2025

Recent Activity

Latest Activity

Annual accounts made up to 31 Dec 2025

2 weeks ago on 19 May 2026

Confirmation statement made on 15 Aug 2025 with no updates

9 months ago on 19 Aug 2025

Annual accounts made up to 31 Dec 2024

1 years ago on 2 Jun 2025

Appointment of Hannah Victoria Tattersall as director on 1 May 2025

1 years ago on 2 May 2025

Termination of Adrian Charles Noel Kemp as director on 1 May 2025

1 years ago on 1 May 2025